Axel Mark
3624
Renascience
4889
Ecomott
3987
Festaria Holdings
2736
Tecnisco
2962
JP Stock MarketDetailed Quotes
4502 Takeda Pharmaceutical
- 4121.0
- -39.0-0.94%
20min DelayMarket Closed Jan 10 15:30 JST
6.56TMarket Cap45.21P/E (Static)
4156.0High4119.0Low3.25MVolume4145.0Open4160.0Pre Close13.44BTurnover4494.052wk High0.21%Turnover Ratio1.59BShares3852.052wk Low181.98EPS TTM6.32TFloat Cap8080.0Historical High45.21P/E (Static)1.53BShs Float2894.5Historical Low91.16EPS LYR0.89%Amplitude192.00Dividend TTM0.94P/B100Lot Size4.66%Div YieldTTM
About Takeda Pharmaceutical Company
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Company Profile
Symbol4502
Company NameTakeda Pharmaceutical
Founded1925-01-29
MarketTSE Prime
Employees49281
Fiscal Year Ends03-31
Address1-1, Nihonbashi-Honcho 2-Chome Chuo-ku
Zip Code540-8645
Phone06-6204-2111
Websitewww.takeda.com
Company Executives
- Name
- Position
- Salary
- Christophe Weber
- Director, President and Chief Executive Officer; Head of Global Business of Takeda Pharmaceuticals U.S.a., Inc.
- 1.70B
- Akiko Amakawa
- Corporate Strategy Officer and Chief Executive Officer Chief of Staff
- --
- Takako Ohyabu
- Chief Global Corporate Affairs and Sustainability Officer
- --
- Milano Furuta
- Director and Chief Financial Officer
- --
- Lauren Duprey
- Chief Human Resources Officer
- --
- Mwana Lugogo
- Chief Ethics and Compliance Officer
- --
- Gabriele Ricci
- Chief Data and Technology Officer
- --
- Marcello Agosti
- Global Business Development Officer
- --
- Dr. Thomas Wozniewski, PhD
- Global Manufacturing and Supply Officer
- --
- Elaine Shannon
- Global Quality Officer
- --
- Andrew S. Plump, M.D.
- Director and President, Research and Development
- 12.00M
- Ramona Sequeira
- President, Global Portfolio Division
- --
- Julie Kim
- President, U.S. Business Unit and U.S. Country Head
- --
- Masami Iijima
- Chairman of the Board
- 43.00M
- Teresa Marie Bitetti
- President, Global Oncology Business Unit
- --
- Asuka Miyabashira
- President, Japan Pharma Business Unit
- --
- Giles Platford
- President, Plasma-Derived Therapies Business Unit
- --
- Emiko Higashi
- Independent Director
- 49.00M
- Jean-Luc Butel
- Independent Director
- 38.00M
- Ian T. Clark
- Independent Director
- 44.00M
- Dr. John M. Maraganore,PhD
- Independent Director
- 39.00M
- Koji Hatsukawa
- Independent Director
- 43.00M
- Miki Tsusaka
- Independent Director
- 32.00M
- Kimberly A. Reed
- Independent Director
- 41.00M
- Yoshiaki Fujimori
- Independent Director
- 40.00M
- Dr. Steven Gillis, Pd.D
- Independent Director
- 44.00M
- Michel Orsinger
- Independent Director
- 46.00M
- Yoshihiro Nakagawa
- Global General Counsel
- --